vTv Therapeutics Inc.

VTVT Nasdaq SEC CIK 1641489
Follow vTv Therapeutics Weekly email: filings, results, news

Financials

Reported figures only · latest: Q2 2026 USD · US GAAP
Revenue, last quarter $0
Net income −$13.1M −115.9% vs same quarter last year
EPS, diluted -
Operating cash flow −$11.4M −124.6% vs same quarter last year
Revenue by quarter
$0
$17K
$0
$0
$0
$0
$36.8M
$0
Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income14 fiscal years
  • Revenue
  • Net income
−$60M−$40M−$20M$0$20MFY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$0−$27M
FY24$1M−$18.5M
FY23$0−$20.3M
FY22$2M−$19.2M
FY21$4M−$13M
FY20$6.4M−$8.5M
FY19$2.8M−$13M
FY18$12.4M−$7.9M
FY17$291K−$16.1M
FY16$634K−$16.4M
FY15$519K−$27.5M
FY14$1.5M−$36.1M
FY13$976K−$48.2M
FY12--
MarginsShare of revenue
  • Operating margin
  • Net margin
−20000%−15000%−10000%−5000%0%FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25--
FY24−2377.6%−1815.3%
FY23--
FY22−1116.9%−949.7%
FY21−540.9%−324.3%
FY20−184.8%−132.5%
FY19−755.9%−471.9%
FY18−159.4%−63.6%
FY17−17416.5%−5547.8%
FY16−8678.2%−2579.2%
FY15−7349.1%−5298.3%
FY14−1865.5%−2330.6%
FY13−3671.4%−4938.8%
FY12--
Free cash flowOperating cash flow minus capital expenditure
−$60M−$40M−$20M$0FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25-
FY24−$25.3M
FY23−$19.1M
FY22−$16M
FY21−$19.3M
FY20−$18M
FY19−$23.1M
FY18−$26.9M
FY17−$44.6M
FY16−$48.3M
FY15−$37.1M
FY14−$30.8M
FY13−$41.9M
FY12-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • vTv Therapeutics
  • Healthcare median
−6000%−4000%−2000%0%FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearvTv TherapeuticsHealthcare median
FY25-−40.6%
FY24−1815.3%−60.7%
FY23-−97.1%
FY22−949.7%−128.5%
FY21−324.3%−129.2%
FY20−132.5%−136.5%
FY19−471.9%−133.7%
FY18−63.6%−173.4%
FY17−5547.8%−176.7%
FY16−2579.2%−164.8%
FY15−5298.3%−183.4%
FY14−2330.6%−133%
FY13−4938.8%−88.5%
FY12-−87.4%

News

No stories filed under vTv Therapeutics yet - coverage appears here as the news feed clusters it.